Lipocine announces financial results for the second quarter ended june 30, 2025

Salt lake city , aug. 5, 2025 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced financial results for the second quarter ended june 30, 2025 and provided a corporate update. neuroactive steroids lpcn 1154 (oral brexanolone product candidate) is a non-invasive, 48-hour treatment option targeted for rapid symptom relief of postpartum depression (ppd), a serious unmet medical need.
LPCN Ratings Summary
LPCN Quant Ranking